180 related articles for article (PubMed ID: 31509117)
1. Enhanced antitumour effect for hepatocellular carcinoma in the advanced stage using a cyclodextrin-sorafenib-chaperoned inclusion complex.
Phan C; Zheng Z; Wang J; Wang Q; Hu X; Tang G; Bai H
Biomater Sci; 2019 Nov; 7(11):4758-4768. PubMed ID: 31509117
[TBL] [Abstract][Full Text] [Related]
2. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
3. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
[TBL] [Abstract][Full Text] [Related]
4. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.
Al-Abdulla R; Lozano E; Macias RIR; Monte MJ; Briz O; O'Rourke CJ; Serrano MA; Banales JM; Avila MA; Martinez-Chantar ML; Geier A; Andersen JB; Marin JJG
Br J Pharmacol; 2019 Mar; 176(6):787-800. PubMed ID: 30592786
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects.
Afifi AM; El-Husseiny AM; Tabashy RH; Khalil MA; El-Houseini ME
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3007-3013. PubMed ID: 31653148
[TBL] [Abstract][Full Text] [Related]
8. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
Romito I; Porru M; Braghini MR; Pompili L; Panera N; Crudele A; Gnani D; De Stefanis C; Scarsella M; Pomella S; Levi Mortera S; de Billy E; Conti AL; Marzano V; Putignani L; Vinciguerra M; Balsano C; Pastore A; Rota R; Tartaglia M; Leonetti C; Alisi A
J Exp Clin Cancer Res; 2021 Nov; 40(1):364. PubMed ID: 34784956
[TBL] [Abstract][Full Text] [Related]
9. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
10. The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach.
Hosseinzadeh F; Ai J; Hajifathali A; Muhammadnejad S; Ebrahimi-Barough S; Seyhoun I; Komeili Movahed T; Shirian S; Hosseinzadeh F; Ahmadpour S; Alijani M; Verdi J
Pharmacol Rep; 2022 Apr; 74(2):379-391. PubMed ID: 35089543
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.
Lee S; Kim JH; Lee JH; Lee JH; Han JK
Eur Radiol; 2018 Jan; 28(1):372-381. PubMed ID: 28752217
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
13. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
Chung CL; Wang SW; Sun WC; Shu CW; Kao YC; Shiao MS; Chen CL
Biochem Pharmacol; 2018 Aug; 154():39-53. PubMed ID: 29678520
[TBL] [Abstract][Full Text] [Related]
15. Diarylheptanoids/sorafenib as a potential anticancer combination against hepatocellular carcinoma: the p53/MMP9 axis of action.
Elmetwalli A; Diab T; Albalawi AN; El-Naggar SA; El-Far AH; Ghedan AR; Alamri ES; Salama AF
Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2501-2517. PubMed ID: 37145126
[TBL] [Abstract][Full Text] [Related]
16. Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
Elsayed MM; Mostafa ME; Alaaeldin E; Sarhan HA; Shaykoon MS; Allam S; Ahmed AR; Elsadek BE
Int J Nanomedicine; 2019; 14():8445-8467. PubMed ID: 31754301
[TBL] [Abstract][Full Text] [Related]
17. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.
Chen F; Fang Y; Zhao R; Le J; Zhang B; Huang R; Chen Z; Shao J
Eur J Med Chem; 2019 Oct; 179():916-935. PubMed ID: 31306818
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic charcterization of sorafenib-induced endoplasmic reticulum stress in human liver cancer cells.
Liu M; Zhou R; Wu X; Xu X; Su M; Yang B
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30415242
[TBL] [Abstract][Full Text] [Related]
19. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Ye J; Zhang R; Chai W; Du X
Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
